PARP1 and COVID-19: In regard to SARS-CoV-2 infection, it is interesting that PARP-1 inhibition has been shown to limit inflammation-induced tissue damage, including acute lung injury in animal models [17], and PARP-1 inhibitors are therefore discussed as a potential treatment option for COVID-19 [16].